Literature DB >> 26649999

Predictive biomarkers for checkpoints, first tests approved.

Ken Garber.   

Abstract

Year:  2015        PMID: 26649999     DOI: 10.1038/nbt1215-1217

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

Review 1.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

2.  Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

3.  PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Authors:  Joel C Sunshine; Peter L Nguyen; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Jessica Esandrio; Haiying Xu; Aleksandra Ogurtsova; Karen B Bleich; Toby C Cornish; Evan J Lipson; Robert A Anders; Janis M Taube
Journal:  Clin Cancer Res       Date:  2017-04-20       Impact factor: 12.531

4.  Genentech's PD-L1 agent approved for bladder cancer.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2016-08-09       Impact factor: 54.908

5.  Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Theresa Scognamiglio; Yao-Tseng Chen
Journal:  Head Neck Pathol       Date:  2017-09-25

6.  PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Authors:  Haidong Tang; Yong Liang; Robert A Anders; Janis M Taube; Xiangyan Qiu; Aditi Mulgaonkar; Xin Liu; Susan M Harrington; Jingya Guo; Yangchun Xin; Yahong Xiong; Kien Nham; William Silvers; Guiyang Hao; Xiankai Sun; Mingyi Chen; Raquibul Hannan; Jian Qiao; Haidong Dong; Hua Peng; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

Review 7.  PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.

Authors:  Junzo Hamanishi; Masaki Mandai; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2016-02-22       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.